Search research articles
Contact Us
Filters
Showing results (21-30 of 61) with videos related to
Page
of 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
Lale Kostakoglu, Morton Coleman, John P Leonard, et al.
Seminars in Oncology
|
October 23, 2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen
Neil H Bander, David M Nanus, Matthew I Milowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
Matthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study
Brian K Link, Peter Martin, Mark S Kaminski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
Neil H Bander, Matthew I Milowsky, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
Shankar Vallabhajosula, Stanley J Goldsmith, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
Peter M Smith-Jones, Shankar Vallabhajosula, Vincent Navarro, et al.
Surgery
|
December 2, 2008
Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma
Nimmi Arora, Harma K Turbendian, Theresa Scognamiglio, et al.
Clinical Genitourinary Cancer
|
May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer
Kevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 4, 2017
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma
Richard B Noto, Daniel A Pryma, Jessica Jensen, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 61) with videos related to
Sort By:
Page
of 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
August 7, 2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease
Lale Kostakoglu, Morton Coleman, John P Leonard, et al.
Seminars in Oncology
|
October 23, 2003
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen
Neil H Bander, David M Nanus, Matthew I Milowsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 3, 2004
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
Matthew I Milowsky, David M Nanus, Lale Kostakoglu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 12, 2010
Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study
Brian K Link, Peter Martin, Mark S Kaminski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2005
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
Neil H Bander, Matthew I Milowsky, David M Nanus, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 6, 2005
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity
Shankar Vallabhajosula, Stanley J Goldsmith, Lale Kostakoglu, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 8, 2003
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor
Peter M Smith-Jones, Shankar Vallabhajosula, Vincent Navarro, et al.
Surgery
|
December 2, 2008
Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma
Nimmi Arora, Harma K Turbendian, Theresa Scognamiglio, et al.
Clinical Genitourinary Cancer
|
May 30, 2006
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer
Kevin A David, Matthew I Milowsky, Lale Kostakoglu, et al.
The Journal of Clinical Endocrinology and Metabolism
|
November 4, 2017
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma
Richard B Noto, Daniel A Pryma, Jessica Jensen, et al.
Page
of 7